$ 25
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity....
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of GPCR is 71 and suggests 185% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
